Remove Compounding Remove Diabetes Remove Drug Pricing
article thumbnail

STAT+: Compounding group sues FDA for removing Lilly’s obesity drug from its shortages list

STAT

A trade group representing large compounding pharmacies has sued the U.S. Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list. Continue to STAT+ to read the full story…

article thumbnail

STAT+: Pharmalittle: We’re reading about compounders suing the FDA, Biogen turning to telehealth, and more

STAT

… A trade group representing large compounding pharmacies has sued the U.S. Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list , STAT tells us. ” A U.S.

article thumbnail

STAT+: Pharmalittle: We’re reading about Lilly lawsuits, Novo Nordisk fires and much more

STAT

We have adjusted our settings to accept postcards and telegrams… After taking legal action last year, Eli Lilly filed even more lawsuits against several spas, compounders and wellness centers over unapproved versions of tirzepatide, which is the active ingredient in Mounjaro and Zepbound,   STAT notes.

Diabetes 274